Papers
1
Total Citations
3
H-Index
1
About
Dr. Linxin Dai is pioneering the intersection of microalgae biotechnology and gastrointestinal therapeutics. Her research focuses on developing biohybrid microrobots for inflammatory bowel disease (IBD) management, addressing critical challenges in targeted drug delivery through the harsh gastrointestinal environment. In her landmark 2026 work, Dr. Dai introduced "stress-trained" microalgae robots equipped with a probiotic backpack and an intestinal brake mechanism—an innovative platform that simultaneously delivers antioxidants and probiotics while precisely controlling release in inflamed intestinal regions. This approach tackles the dual pathology of IBD: elevated reactive oxygen species and microbial dysbiosis. Though early in her career, her flagship paper has already garnered 3 citations, signaling growing recognition of her translational vision. Dr. Dai’s contributions are particularly notable for their elegant engineering solution to a longstanding delivery problem—protecting fragile bioactive cargo through gastric acid while ensuring site-specific action. Her work represents a paradigm shift from passive drug carriers to active, stress-responsive biological robots, opening new avenues for treating chronic inflammatory conditions with living therapeutics.
Research Focus
Key Achievements
Top Papers
- 1